Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins
Sponsor: Ryazan State Medical University
Summary
The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).
Official title: Study of the Effects of Bioflavonoids on Venous Wall Remodeling in Patients With Varicose Veins of the Lower Extremities
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-04-01
Completion Date
2026-05-01
Last Updated
2025-07-23
Healthy Volunteers
Yes
Interventions
"Venarus®" (diosmin and hesperidin)
"Venarus®" (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months
Endovenous laser ablation (EVLA) with miniphlebectomy
Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
Elastic compression
All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
Locations (1)
RyazanSMU
Ryazan, Russia